The purpose of this study is to compare the effectiveness of up to 27 weeks of post-surgical observation to up to 27 weeks of post-surgery pembrolizumab at reducing the risk of breast cancer coming back or death in patients with early-stage TNBC who achieved a pCR after preoperative chemotherapy in combination with pembrolizumab.
Learn more about the A012103/OptimICE-pCR trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
